We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sen. Charles Grassley (R-Iowa) is calling on the Justice Department to reconsider testifying before the House Judiciary Committee on its settlement with Mylan, which resolved allegations that the company overcharged Medicaid for its allergy therapy, the EpiPen. Read More
The UK Court of Appeal affirmed an earlier ruling that invalidates Pfizer’s patent claims for Lyrica, saying generic versions will not lead to any infringement. Read More
A proposal to extend the market exclusivity of new drugs approved in India from four years to 10 is dividing the industry, as some argue that the measure would promote safety and others contend it delays generic competition. Read More
The PTO’s Patient Trial and Appeal Board said it was not persuaded by Coherus Biosciences’ challenge over the patentability of methods for manufacturing Humira, and ruled in favor of AbbVie in a trial proceeding. Read More
The U.S. Supreme Court refused to hear appeals brought by Purdue Pharma LP for a patent infringement case centered on reformulations of the painkiller OxyContin, clearing several barriers to the development of generics. Read More
The Federal Trade Commission is backing Mylan’s request for a rehearing before a panel of appellate judges on the dismissal of an antitrust lawsuit against Warner Chilcott and Mayne Pharmaceuticals. Read More
A nearly two-year antitrust investigation by the Justice Department that involves more than a dozen generics makers could result in price-collusion charges before the year ends, according to a source familiar with the matter. Read More
The UK Court of Appeal affirmed an earlier ruling that invalidated Pfizer’s patent claims for Lyrica and ruled generics would not lead to infringements. Read More
Drugmakers have expressed concern about the German government’s proposal to restrict drug pricing — contending that the measure penalizes research and development. Read More